Wegovy weight loss results: what TikTok jokes hide about GLP-1 reality

What did @sierraxliyah actually say?

In a 7-month Wegovy update, @sierraxliyah claims she lost 70 pounds since June, experienced zero side effects, and is now tapering off the medication on her doctor's guidance. She also urges viewers to lift weights, resistance train, and prioritize protein while on Wegovy. Those are the four things worth examining here.

She describes Wegovy as "kind of like a shot, kind of like Ozempic a little bit, but it's not Ozempic" — which is technically accurate in the sense that both contain semaglutide but are FDA-approved for different indications. She says she is currently on "the 1.7 shot" and plans to taper down through 1.0, 0.7, 0.5, and 0.25 mg before stopping. She's transparent that this is her doctor's protocol, not her own invention. That disclosure matters.

Does the science back this up?

The 70-pound loss over 7 months is aggressive but not impossible, though it sits above what clinical trials typically show as an average. Resistance training and protein intake advice, however, is genuinely well-supported and often underemphasized in GLP-1 content.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that participants on 2.4 mg semaglutide lost an average of about 14.9% of body weight over 68 weeks, with lifestyle intervention. Seventy pounds in 7 months could represent a higher-than-average response, which does happen, but viewers should not treat her result as a benchmark. Individual responses to semaglutide vary considerably based on starting weight, adherence, diet, activity level, and metabolic factors.

On the muscle loss point: a 2023 paper by Ida et al. in Diabetes, Obesity and Metabolism confirmed that GLP-1 receptor agonists can contribute to lean mass loss alongside fat loss, making resistance training and adequate protein intake genuinely important co-interventions, not just lifestyle fluff. She gets credit for emphasizing this.

What did they get wrong (or right)?

The "no side effects" claim is where this video gets complicated. Saying she personally had no nausea or vomiting is fair, that is her experience. But framing it as broadly as "I've had no side effects" could mislead viewers into thinking Wegovy is uniformly well-tolerated. It is not.

The STEP program trials documented gastrointestinal side effects in a majority of participants. Nausea affected roughly 44% of semaglutide users versus 16% on placebo (Wilding et al., 2021, NEJM). Diarrhea, constipation, and fatigue are also common. Some patients discontinue treatment because of these effects. Her experience is real, but it is not typical enough to be presented as the norm without qualification.

Her tapering protocol, going from 1.7 mg down through progressively lower doses, is not a standard FDA-approved Wegovy dosing schedule. The approved maintenance dose is 2.4 mg weekly. What she is describing sounds like a personalized physician-directed plan, which may be appropriate for her situation, but she does not hold a degree and neither does her viral TikTok. Viewers should not replicate her taper without their own provider's direction.

What she got right: the distinction between Wegovy and Ozempic, the emphasis on resistance training and protein, and the repeated mention that her doctor is guiding her decisions. That last part is doing a lot of work.

What should you actually know?

GLP-1 medications like semaglutide can produce significant weight loss in appropriate candidates, but outcomes vary widely and the drug works best as part of a broader lifestyle plan, not as a standalone fix. @sierraxliyah's results are real to her, but 70 pounds in 7 months should not become your personal target or timeline.

Side effects are common and real. The absence of nausea in one person does not predict your experience. If you are considering Wegovy, have an honest conversation with a licensed provider about your full medical history, current medications, and realistic expectations.

Tapering off GLP-1 medications is also an area with limited long-term evidence. A 2022 study by Wilding et al. in Diabetes, Obesity and Metabolism found that participants who discontinued semaglutide regained about two-thirds of their lost weight within a year. Whether a gradual taper changes that outcome is not yet well-established in peer-reviewed literature. That does not mean tapering is wrong, it means the data is not there yet.

Finally: Wegovy and Ozempic both contain semaglutide, but they are not interchangeable. They have different FDA approvals, dosing schedules, and clinical indications. Do not substitute one for the other based on availability or price without provider guidance.